Easywell Biomedicals, Inc. (1799) AI Stock Analysis

Easywell Biomedicals, Inc.

(TPEx:1799)

Select Model

Rating:45Neutral

Price Target:TWD 24.00▼(-2.24% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by continued unprofitability, deteriorated margins, negative valuation metrics, and bearish technical momentum. Improved cash generation and reduced leverage provide support, but the overall profile remains a high-risk turnaround.

Positive Factors

Revenue GrowthThe sharp 2025 revenue rebound indicates improving demand and market traction in Easywell’s IVD and biomedical activities. If sustained, stronger sales can provide operating leverage, support investment in products and services, and improve the company’s ability to convert growth into future profitability.

Negative Factors

Persistent Net LossesContinued operating and net losses show that revenue growth has not yet translated into a self-sustaining earnings model. Persistent losses can constrain reinvestment, weaken returns on capital, and make the durability of the current turnaround dependent on further margin improvement.

Easywell Biomedicals, Inc. (1799) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.14B
Dividend Yield: ―
Average Volume (3M): 121.17K
Price to Earnings (P/E): -264.1
Beta (1Y): 0.54
Revenue Growth: 59.53%
EPS Growth: 83.16%
Country: TW
Employees: 3,118
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Easywell Biomedicals, Inc. Business Overview & Revenue Model

Company Description

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develo...

Easywell Biomedicals, Inc. Financial Statement Overview

Summary

Improving revenue, positive EBITDA, stronger operating cash flow, free cash flow recovery, and lower leverage are offset by continued net losses, sharply lower gross margin, negative ROE, and debt coverage below half.

Income Statement

35Negative

Balance Sheet

58Neutral

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	799.94M	597.41M	540.44M	271.63M	178.90M	197.28M
Gross Profit	374.94M	245.71M	299.40M	170.72M	76.31M	50.43M
EBITDA	76.92M	23.93M	12.75M	-85.50M	-84.48M	-82.70M
Net Income	-16.27M	-73.14M	-97.47M	-144.82M	-161.00M	-150.39M
Balance Sheet
Total Assets	1.29B	1.29B	1.51B	1.21B	1.17B	1.26B
Cash, Cash Equivalents and Short-Term Investments	484.70M	451.69M	466.10M	348.03M	339.54M	439.28M
Total Debt	386.54M	425.91M	564.28M	386.34M	349.96M	325.50M
Total Liabilities	568.45M	589.74M	766.17M	589.99M	402.60M	351.82M
Stockholders Equity	709.28M	690.67M	718.61M	612.81M	738.46M	873.66M
Cash Flow
Free Cash Flow	128.13M	109.37M	-171.79M	-170.00M	-60.99M	-136.02M
Operating Cash Flow	141.91M	124.78M	-159.04M	-151.45M	-53.50M	-128.31M
Investing Cash Flow	-24.10M	-25.04M	-47.66M	87.46M	72.66M	-182.54M
Financing Cash Flow	-48.80M	-142.70M	263.06M	177.84M	-10.55M	320.31M

Easywell Biomedicals, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1799 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1737	67Neutral	TWD 5.98B	15.74	―	4.71%	-2.24%	12.99%
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
TW:4167	60Neutral	TWD 6.30B	7.86	―	4.18%	-0.05%	64.82%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4119	48Neutral	TWD 5.85B	95.69	―	1.55%	-18.83%	-87.54%
TW:1799	45Neutral	TWD 6.24B	-264.14	―	―	59.53%	83.16%

* General Sector Average

Performance Comparison

TW:1799 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1799	Easywell Biomedicals, Inc.	24.55	-9.10	-27.04%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.76	6.19%
TW:1737	Taiyen Biotech Co. Ltd.	29.75	-0.73	-2.39%
TW:4119	SCI Pharmtech Corp.	48.50	-0.61	-1.25%
TW:4167	Savior Lifetec Corp.	19.25	2.48	14.77%
TW:7754	Annji Pharmaceutical Co., Ltd.	69.40	24.75	55.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Easywell Biomedicals, Inc. AI Stock Analysis